{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:07:40Z","timestamp":1762459660457,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"The Gutsy Incorporated Victoria Charitable Organisation"},{"name":"The Australian National Health and Medical Research Council NHMRC","award":["106444"],"award-info":[{"award-number":["106444"]}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.drudis.2018.09.001","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T04:02:53Z","timestamp":1536292973000},"page":"37-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["A well-tolerated and rapidly acting thiopurine for IBD?"],"prefix":"10.1016","volume":"24","author":[{"given":"Timothy H.J.","family":"Florin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth D.","family":"Jambhrunkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Henman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirali","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2018.09.001_bib0005","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2018.09.001_bib0010","article-title":"Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study","author":"Eriksson","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2018.09.001_bib0015","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn\u2019s disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2018.09.001_bib0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/gast.2000.18144","article-title":"A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn\u2019s disease","volume":"119","author":"Markowitz","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2018.09.001_bib0025","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.09.001_bib0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2008.08.028","article-title":"Azathioprine withdrawal in patients with Crohn\u2019s disease maintained on prolonged remission: a high risk of relapse","volume":"7","author":"Treton","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2018.09.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2013.06.023","article-title":"Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study","volume":"11","author":"Rubin","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2018.09.001_bib0040","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.gastro.2013.03.044","article-title":"Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2018.09.001_bib0045","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/ibd\/izy047","article-title":"Methotrexate and thioguanine rescue therapy for conventional thiopurine failing ulcerative colitis patients: a multi-center database study on tolerability and effectiveness","volume":"24","author":"Meijer","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.drudis.2018.09.001_bib0050","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/jgh.14000","article-title":"Prolonged azathioprine treatment reduces the need for surgery in early Crohn\u2019s disease","volume":"33","author":"Qiu","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2018.09.001_bib0055","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1365-2036.2008.03788.x","article-title":"Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease","volume":"28","author":"Ansari","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2018.09.001_bib0060","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2018.09.001_bib0065","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1053\/j.gastro.2007.04.075","article-title":"Crohn\u2019s disease patients\u2019 risk\u2013benefit preferences: serious adverse event risks versus treatment efficacy","volume":"133","author":"Johnson","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2018.09.001_bib0070","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/humupd\/dmx034","article-title":"The associations of thiopurines with male fertility and paternally exposed offspring: a systematic review and meta-analysis","volume":"24","author":"Simsek","year":"2018","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.drudis.2018.09.001_bib0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0016-5085(99)70445-2","article-title":"Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn\u2019s disease. North American Azathioprine Study Group","volume":"117","author":"Sandborn","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2018.09.001_bib0080","first-page":"756","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"35","author":"Tiede","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2018.09.001_bib0085","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/01.ftd.0000169061.52715.3e","article-title":"Thiopurine therapies: problems, complexities and progress with monitoring thioguanine nucleotides","volume":"27","author":"Duley","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.drudis.2018.09.001_bib0090","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1097\/MIB.0000000000000206","article-title":"Splitting a therapeutic dose of thioguanine may avoid liver toxicity and be an efficacious treatment for severe inflammatory bowel disease: a 2-center observational cohort study","volume":"20","author":"Pavlidis","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.drudis.2018.09.001_bib0095","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1097\/MIB.0000000000000869","article-title":"The prevalence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with thioguanine is not associated with clinically significant liver disease","volume":"22","author":"Asseldonk","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.drudis.2018.09.001_bib0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jhep.2017.02.031","article-title":"Reversibility of chemotherapy-related liver injury","volume":"67","author":"Vigano","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2018.09.001_bib0105","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4049\/jimmunol.176.1.640","article-title":"Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins","volume":"176","author":"Poppe","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2018.09.001_bib0110","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/gut.2008.157339","article-title":"Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines","volume":"58","author":"Ben-Horin","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2018.09.001_bib0115","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/gutjnl-2012-302274","article-title":"A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity","volume":"62","author":"Oancea","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2018.09.001_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050054","article-title":"Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis","volume":"5","author":"Heazlewood","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.drudis.2018.09.001_bib0125","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/mi.2010.74","article-title":"An intestinal epithelial defect conferring ER stress results in inflammation involving both innate and adaptive immunity","volume":"4","author":"Eri","year":"2011","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.drudis.2018.09.001_bib0130","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20121268","article-title":"Glucocorticoids alleviate intestinal ER stress by enhancing protein folding and degradation of misfolded proteins","volume":"210","author":"Das","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drudis.2018.09.001_bib0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/gutjnl-2015-310874","article-title":"Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism","volume":"66","author":"Oancea","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2018.09.001_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gutjnl-2016-312450","article-title":"Microbiota: relevant player in thiopurine metabolisation?","volume":"66","author":"Atreya","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2018.09.001_bib0145","unstructured":"Florin, T. et al. (2017) Novel Formulation and Treatment Methods. WIPO: PCT\/AU2016\/050910"},{"key":"10.1016\/j.drudis.2018.09.001_bib0150","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.drudis.2018.09.001_bib0155","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/1756-185X.12188","article-title":"Risk of tuberculosis with anti-tumor necrosis factor-\u03b1 therapy: substantially higher number of patients at risk in Asia","volume":"17","author":"Navarra","year":"2014","journal-title":"Int. J. Rheum Dis."},{"key":"10.1016\/j.drudis.2018.09.001_bib0160","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/jgh.13669","article-title":"Infliximab-induced tuberculosis in patients with UC: experience from India \u2013 a country with high prevalence of tuberculosis","volume":"32","author":"Puri","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.drudis.2018.09.001_bib0165","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.09.001_bib0170","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1093\/ecco-jcc\/jjv117","article-title":"Health care cost analysis in a population-based inception cohort of inflammatory bowel disease patients in the first year of diagnosis","volume":"9","author":"Niewiadomski","year":"2015","journal-title":"J. Crohns Colitis"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618302903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618302903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:40:57Z","timestamp":1761223257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618302903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1359644618302903"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2018.09.001","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A well-tolerated and rapidly acting thiopurine for IBD?","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2018.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}